Stoke Therapeutics (NASDAQ:STOK) Shares Down 5% – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOKGet Free Report)’s stock price dropped 5% on Wednesday . The stock traded as low as $11.35 and last traded at $11.50. Approximately 82,661 shares were traded during trading, a decline of 89% from the average daily volume of 739,745 shares. The stock had previously closed at $12.10.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Leerink Partners started coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Finally, Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and an average target price of $20.83.

Read Our Latest Research Report on STOK

Stoke Therapeutics Trading Down 2.6 %

The stock has a market cap of $623.95 million, a price-to-earnings ratio of -5.61 and a beta of 0.95. The company has a 50 day simple moving average of $12.51 and a 200-day simple moving average of $13.61.

Stoke Therapeutics (NASDAQ:STOKGet Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Equities analysts forecast that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 2,586 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $33,592.14. Following the completion of the transaction, the insider now owns 44,746 shares in the company, valued at $581,250.54. This trade represents a 5.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This represents a 17.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,000,349 shares of company stock worth $28,031,296 over the last three months. 11.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of STOK. BNP Paribas Financial Markets boosted its stake in shares of Stoke Therapeutics by 1,589.7% during the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after purchasing an additional 71,647 shares during the period. RTW Investments LP boosted its holdings in Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after acquiring an additional 427,447 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Stoke Therapeutics by 54.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock valued at $1,266,000 after buying an additional 36,240 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after buying an additional 1,123,500 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Stoke Therapeutics by 528.6% in the second quarter. Millennium Management LLC now owns 289,067 shares of the company’s stock worth $3,905,000 after acquiring an additional 243,083 shares during the period.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

See Also

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.